Orasis Pharmaceuticals developed Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a corrective eye drop indicated for the treatment of presbyopia in adults. Qlosi uses the lowest effective concentration of pilocarpine approved and a multi-faceted vehicle, does not contain an antimicrobial preservative, and improves near visual acuity via pupil modulation (a "pinhole effect"). The company emphasizes a balance of efficacy, safety, and comfort for patients seeking an alternative to reading glasses. Orasis plans to use the new financing to support the commercial launch of Qlosi. The company is led by industry executives and eye care professionals and is funded by a diverse group of life-science and healthcare investors. Orasis has offices in the United States and Israel. Orasis Pharmaceuticals, based in Herzliya, Israel, is developing a proprietary ophthalmic formulation intended to treat presbyopia symptoms. Its lead candidate is an eye drop designed to achieve an optimal balance between efficacy, safety and comfort. The company plans to use the Series C proceeds to advance that lead eye drop through completion of Phase 3 clinical trials and to fund pre-commercialization activities ahead of a potential product launch. Orasis is led by CEO Elad Kedar. The company positions its novel formulation to potentially make it an emerging leader in the presbyopia space. It closed a $30M Series C financing to support these programs. Orasis Pharmaceuticals, led by CEO Elad Kedar and based in Herzliya, Israel, is a clinical-stage company developing an innovative eye drop to treat presbyopia as an alternative to reading glasses. Its lead product candidate, CSF-1, is being advanced through clinical development. The company intends to use the new funding to complete its Phase 2b trial of CSF-1, prepare for a Phase 3 trial, and continue pre-commercial activities ahead of a potential launch. Orasis closed a financing that supports these near-term clinical and commercial milestones. The company added board members from its new investors as part of the financing.

Total raised

$126M

Funding rounds

4

Latest round

Series D

Latest activity

Oct 2024